102 related articles for article (PubMed ID: 17260902)
21. Drug delivery strategies for poorly water-soluble drugs: the industrial perspective.
van Hoogevest P; Liu X; Fahr A
Expert Opin Drug Deliv; 2011 Nov; 8(11):1481-500. PubMed ID: 21895540
[TBL] [Abstract][Full Text] [Related]
22. Microfluidic Preparation of Nanoparticles Using Poly(ethylene Glycol)-distearoylphosphatidylethanolamine for Solubilizing Poorly Soluble Drugs.
Terada T; Kanou M; Hashimoto Y; Tanimoto M; Sugimoto M
J Pharm Sci; 2022 Jun; 111(6):1709-1718. PubMed ID: 34863973
[TBL] [Abstract][Full Text] [Related]
23. Drug loading into porous calcium carbonate microparticles by solvent evaporation.
Preisig D; Haid D; Varum FJ; Bravo R; Alles R; Huwyler J; Puchkov M
Eur J Pharm Biopharm; 2014 Aug; 87(3):548-58. PubMed ID: 24568926
[TBL] [Abstract][Full Text] [Related]
24. Using the polymer partitioning method to probe the thermodynamic activity of poorly water-soluble drugs solubilized in model lipid digestion products.
Boyd BJ; Porter CJ; Charman WN
J Pharm Sci; 2003 Jun; 92(6):1262-71. PubMed ID: 12761815
[TBL] [Abstract][Full Text] [Related]
25. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology.
Merisko-Liversidge E; Liversidge GG
Adv Drug Deliv Rev; 2011 May; 63(6):427-40. PubMed ID: 21223990
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of cyclodextrin solubilization of drugs.
Loftsson T; Hreinsdóttir D; Másson M
Int J Pharm; 2005 Sep; 302(1-2):18-28. PubMed ID: 16099118
[TBL] [Abstract][Full Text] [Related]
27. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.
Vasconcelos T; Sarmento B; Costa P
Drug Discov Today; 2007 Dec; 12(23-24):1068-75. PubMed ID: 18061887
[TBL] [Abstract][Full Text] [Related]
28. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs.
Hu L; Tang X; Cui F
J Pharm Pharmacol; 2004 Dec; 56(12):1527-35. PubMed ID: 15563759
[TBL] [Abstract][Full Text] [Related]
29. Analysis of nucleation kinetics of poorly water-soluble drugs in presence of ultrasound and hydroxypropyl methyl cellulose during antisolvent precipitation.
Dalvi SV; Dave RN
Int J Pharm; 2010 Mar; 387(1-2):172-9. PubMed ID: 20026199
[TBL] [Abstract][Full Text] [Related]
30. A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique.
Li-Hong W; Xin C; Hui X; Li-Li Z; Jing H; Mei-Juan Z; Jie L; Yi L; Jin-Wen L; Wei Z; Gang C
Int J Pharm; 2013 Sep; 454(1):135-42. PubMed ID: 23871738
[TBL] [Abstract][Full Text] [Related]
31. Development and characterization of phospholipid-stabilized submicron aqueous dispersions of coenzyme Q₁₀ presenting continuous vibrating-mesh nebulization performance.
Carvalho TC; McCook JP; Narain NR; McConville JT
J Liposome Res; 2013 Dec; 23(4):276-90. PubMed ID: 23772691
[TBL] [Abstract][Full Text] [Related]
32. In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.
Devraj R; Williams HD; Warren DB; Mohsin K; Porter CJ; Pouton CW
Eur J Pharm Sci; 2013 Jul; 49(4):748-60. PubMed ID: 23684915
[TBL] [Abstract][Full Text] [Related]
33. Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus.
Joe JH; Lee WM; Park YJ; Joe KH; Oh DH; Seo YG; Woo JS; Yong CS; Choi HG
Int J Pharm; 2010 Aug; 395(1-2):161-6. PubMed ID: 20580799
[TBL] [Abstract][Full Text] [Related]
34. Inclusion complexation of diazepam with different cyclodextrins in formulations for parenteral use.
Holvoet C; Heyden YV; Plaizier-Vercammen J
Pharmazie; 2005 Aug; 60(8):598-603. PubMed ID: 16124403
[TBL] [Abstract][Full Text] [Related]
35. Cyclosporin pro-dispersion liposphere formulation.
Avramoff A; Khan W; Ezra A; Elgart A; Hoffman A; Domb AJ
J Control Release; 2012 Jun; 160(2):401-6. PubMed ID: 22227025
[TBL] [Abstract][Full Text] [Related]
36. Dissolution-modulating mechanism of pH modifiers in solid dispersion containing weakly acidic or basic drugs with poor water solubility.
Tran PH; Tran TT; Lee KH; Kim DJ; Lee BJ
Expert Opin Drug Deliv; 2010 May; 7(5):647-61. PubMed ID: 20205605
[TBL] [Abstract][Full Text] [Related]
37. Evolution of supersaturation of amorphous pharmaceuticals: nonlinear rate of supersaturation generation regulated by matrix diffusion.
Sun DD; Lee PI
Mol Pharm; 2015 Apr; 12(4):1203-15. PubMed ID: 25775257
[TBL] [Abstract][Full Text] [Related]
38. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation.
Ashok B; Arleth L; Hjelm RP; Rubinstein I; Onyüksel H
J Pharm Sci; 2004 Oct; 93(10):2476-87. PubMed ID: 15349957
[TBL] [Abstract][Full Text] [Related]
39. Nanoprecipitation for Poorly Water-Soluble Drugs.
Nguyen TNG; Tran VT; Duan W; Tran PHL; Tran TTD
Curr Drug Metab; 2017; 18(11):1000-1015. PubMed ID: 28982324
[TBL] [Abstract][Full Text] [Related]
40. An in vitro kinetic method for detection of precipitation of poorly soluble drugs.
Wu Z; Tucker IG; Razzak M; Medlicott NJ
Int J Pharm; 2005 Nov; 304(1-2):1-3. PubMed ID: 16198520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
